|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
143,520,000 |
Market
Cap: |
63.51(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0.4425 - $0.4425 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile EyePoint Pharmaceuticals is a pharmaceutical company focused on developing and commercializing therapeutics for patients with eye disorders. Co.'s primary product candidate, EYP-19, is a potential sustained delivery intravitreal anti-VEGF treatment targeting wet age-related macular degeneration. YUTIQ 50 (fluocinolone acetonide intravitreal implant) 0.18 mg for intravitreal injection, is for the treatment of non-infectious uveitis affecting the posterior segment of the eye. DEXYCU® (dexamethasone intraocular suspension) 9%, for intraocular administration, is indicated for the treatment of post-operative ocular inflammation.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
1,431,765 |
4,794,057 |
4,794,057 |
4,794,057 |
Total Buy Value |
$20,571,167 |
$89,496,413 |
$89,496,413 |
$89,496,413 |
Total People Bought |
1 |
1 |
1 |
1 |
Total Buy Transactions |
2 |
6 |
6 |
6 |
Total Shares Sold |
11,625 |
6,173,124 |
6,733,654 |
6,733,654 |
Total Sell Value |
$147,045 |
$121,413,458 |
$128,500,645 |
$128,500,645 |
Total People Sold |
1 |
7 |
8 |
8 |
Total Sell Transactions |
1 |
25 |
33 |
33 |
End Date |
2024-02-25 |
2023-11-24 |
2023-05-26 |
2022-05-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Ashton Paul |
President & CEO |
|
2014-06-12 |
4 |
OE |
$1.13 |
$10,848 |
D/D |
9,600 |
450,341 |
|
- |
|
Freedman Lori |
VP Corp. Affairs, GC and Sec |
|
2014-05-05 |
4 |
AS |
$4.01 |
$14,035 |
D/D |
(3,500) |
96,423 |
|
- |
|
Freedman Lori |
VP Corp. Affairs, GC and Sec |
|
2014-05-05 |
4 |
OE |
$1.81 |
$6,335 |
D/D |
3,500 |
99,923 |
|
- |
|
Ashton Paul |
President & CEO |
|
2014-05-05 |
4 |
AS |
$4.01 |
$14,035 |
D/D |
(3,500) |
440,741 |
|
- |
|
Ashton Paul |
President & CEO |
|
2014-05-05 |
4 |
OE |
$1.13 |
$3,955 |
D/D |
3,500 |
444,241 |
|
- |
|
Hopper Paul |
Director |
|
2012-10-01 |
4 |
B |
$1.61 |
$16,150 |
I/I |
10,000 |
10,000 |
2.1 |
- |
|
Ashton Paul |
President and CEO |
|
2009-11-19 |
4 |
A |
$0.00 |
$0 |
D/D |
27,431 |
457,522 |
|
- |
|
Freedman Lori |
VP Corp Affairs,Gen Coun & Sec |
|
2009-06-25 |
4 |
A |
$0.00 |
$0 |
D/D |
31,616 |
96,423 |
|
- |
|
Freedman Lori |
VP Corp Affairs,Gen Coun & Sec |
|
2008-06-19 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
64,807 |
|
- |
|
Mazzo David J |
Director |
|
2008-06-19 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
500 |
|
- |
|
Ashton Paul |
Managing DirectorOfficer |
|
2008-06-19 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
16,781 |
|
- |
|
Ashton Paul |
Managing DirectorOfficer |
|
2008-06-19 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
413,310 |
|
- |
|
Soja Michael |
VP Finance, CFO & TreasurerOff |
|
2008-06-19 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
69,011 |
|
- |
|
Pfizer Inc |
10% Owner |
|
2007-08-27 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
74,483,748 |
|
- |
|
Mazzo David J |
Director |
|
2007-07-13 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
20,000 |
|
- |
|
Freedman Lori |
VP Corp Affairs,Gen Coun & Sec |
|
2007-07-13 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
2,592,320 |
|
- |
|
Ashton Paul |
Managing DirectorOfficer |
|
2007-07-13 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
671,270 |
|
- |
|
Ashton Paul |
Managing DirectorOfficer |
|
2007-07-13 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
16,532,410 |
|
- |
|
Soja Michael |
VP Finance, CFO & TreasurerOff |
|
2007-07-13 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
2,760,460 |
|
- |
|
Finlay Aaron |
SecretaryOfficer |
|
2007-07-13 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
15,000 |
|
- |
|
270 Records found
|
|
Page 11 of 11 |
|
|